# Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS

> **NCT07457775** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 24 (estimated)

## Conditions studied

- Soft Tissue Sarcoma (Excluding GIST)

## Interventions

- **DRUG:** Irinotecan Hydrochloride Liposome Injection(II) combined with temozolomide and bevacizuma

## Key facts

- **NCT ID:** NCT07457775
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07457775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07457775, "Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07457775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*